How should the dosage and usage of mivamutide injection be reasonably arranged?

Mifamurtide injection (Mifamurtide) is mainly used as an auxiliary immunotherapy drug after osteosarcoma resection. Its dosage and dosage regimen have been verified by many studies in clinical practice, emphasizing regularity and persistence to achieve maximum efficacy. The recommended dose is calculated based on the patient's body surface area (Body Surface Area, BSA), and the standard dose is 2 mg per square meter of body surface area.

The administration method is intravenous injection, and the single injection time is 1 hour to ensure that the drug enters the blood circulation slowly and evenly and to reduce infusion-related adverse reactions. The entire dosing cycle is divided into two phases: in the first 12 weeks, injections are given twice a week, with an interval of at least 3 days between the two injections; in the subsequent 24-week phase, injections are given once a week. The total treatment course was 36 weeks, with a total of 48 injections completed.

This dosage regimen is designed to continuously activate the body's monocyte-macrophage system, enhance immune surveillance capabilities, and reduce the risk of postoperative tumor recurrence. Frequent early administration helps quickly establish an immune defense line, and subsequent maintenance injections ensure the persistence and stability of the immune effect.

During treatment, patients should undergo regular hematology and liver and kidney function monitoring to observe drug tolerance and potential side effects. When injecting, medical staff need to pay attention to the establishment of intravenous access and control of infusion speed to prevent infusion reactions. If infusion-related allergies or other adverse reactions occur, the dose should be adjusted or treatment suspended based on severity.

Generally speaking, the dosage and usage of mivamutin injection emphasize individualization, standardization and continuity, and maximize the immune auxiliary effect of the drug through scientific dosing plan to help osteosarcoma patients improve the cure rate and quality of life. Patients should strictly implement the medication plan under the guidance of professional doctors to ensure safe and effective treatment.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/mepact